Clinical Transplantation,
Journal Year:
2024,
Volume and Issue:
38(7)
Published: July 1, 2024
Severe
alcohol-associated
hepatitis
(SAH)
represents
a
lethal
subset
of
liver
disease.
Although
corticosteroids
are
recommended
by
guidelines,
their
efficacy
and
safety
remain
questionable
so
transplantation
(LT)
has
been
increasingly
utilized.
The
timing
indication
corticosteroid
use,
specifically
in
patients
being
considered
for
LT
requires
further
clarification.
Hepatology International,
Journal Year:
2025,
Volume and Issue:
19(1), P. 1 - 69
Published: Feb. 1, 2025
Acute-on-chronic
liver
failure
(ACLF)
is
a
condition
associated
with
high
mortality
in
the
absence
of
transplantation.
There
have
been
various
definitions
proposed
worldwide.
The
first
consensus
report
working
party
Asian
Pacific
Association
for
Study
Liver
(APASL)
set
2004
on
ACLF
was
published
2009,
and
"APASL
Research
Consortium
(AARC)"
formed
2012.
AARC
database
has
prospectively
collected
nearly
10,500
cases
from
countries
Asia-Pacific
region.
This
instrumental
developing
score
grade
ACLF,
concept
'Golden
Therapeutic
Window',
'transplant
window',
plasmapheresis
as
treatment
modality.
Also,
data
key
to
identifying
pediatric
ACLF.
European
Liver-Chronic
Failure
(EASL
CLIF)
North
American
End
Stage
Disease
(NACSELD)
West
added
concepts
organ
infection
precipitants
development
CLIF-Sequential
Organ
Assessment
(SOFA)
NACSELD
scores
prognostication.
Chinese
Group
Severe
Hepatitis
B
(COSSH)
COSSH-ACLF
criteria
manage
hepatitis
b
virus-ACLF
without
cirrhosis.
literature
supports
these
be
equally
effective
their
respective
cohorts
patients
mortality.
To
overcome
differences
develop
global
consensus,
APASL
took
initiative
invited
stakeholders,
including
opinion
leaders
Asia,
EASL
AASLD,
other
researchers
field
identify
issues
an
evidence-based
document.
document
presented
hybrid
format
at
annual
meeting
Kyoto
March
2024.
'Kyoto
Consensus'
below
carries
final
recommendations
along
relevant
background
information
areas
requiring
future
studies.
The American Journal of Gastroenterology,
Journal Year:
2023,
Volume and Issue:
119(5), P. 864 - 874
Published: Nov. 9, 2023
Critically
ill
patients
with
cirrhosis
admitted
to
the
intensive
care
unit
(ICU)
are
usually
on
broad-spectrum
antibiotics
because
of
suspected
infection
or
as
a
hospital
protocol.
It
is
unclear
if
additional
rifaximin
has
any
synergistic
effect
in
ICU
acute
overt
hepatic
encephalopathy
(HE).
Expert Review of Gastroenterology & Hepatology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 23, 2025
In
carefully
selected
individuals,
outcomes
of
early
deceased
donor
liver
transplantation
(<6
months
sobriety)
for
severe
alcohol-associated
hepatitis
(AAH)
are
similar
to
transplant
other
indications.
There
is
increasing
interest
in
the
expansion
living
(LDLT)
AAH.
A
literature
search
was
conducted
PubMed
using
terms
'alcoholic
hepatitis,'
'alcohol-associated
'acute
failure'
and
'living
transplant'
between
1995
2025.
Additional
data
sources
were
International
Registry
Organ
Donation
Transplantation,
Scientific
Transplant
Recipients.
We
summarize
global
burden
disease
(ALD),
emergence
LT
Donor-
recipient-specific
factors
explored,
as
well
societal
considerations
including
equitable
allocation
health
system
financial
impact.
Finally,
current
practices
ALD
by
region
reviewed,
with
a
focus
on
readiness
LDLT
Use
AAH
infrequent,
but
countries
experience
and/or
acute
failure
most
poised
expand
Progress
needed
assessing
risk
return
harmful
drinking
improving
management
alcohol
use
disorder.
Transplantation,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 24, 2025
Background.
Alcohol-associated
liver
disease
(ALD)
is
the
leading
indication
for
transplantation
(LT)
in
Western
world.
Although
6
mo
of
abstinence
no
longer
a
criterion
patients
with
ALD,
outcomes
living
donor
LT
(LDLT)
versus
deceased
(DDLT)
are
not
well
established.
Methodss.
We
performed
an
intention-to-treat
analysis
to
evaluate
impact
listing
and
pursuing
primary
LDLT
(pLDLT)
compared
DDLT
(pDDLT).
The
endpoint
was
overall
survival
from
date
listing,
evaluated
using
Cox
regression
(hazard
ratios).
Results.
Two
hundred
thirty-three
ALD
were
listed
LT,
which
27
(12%)
pLDLT.
median
model
end-stage
(MELD)
score
at
20
Na-MELD
24,
4.5
mo,
128
(55%)
underwent
transplantation.
There
statistically
significant
adjusted
difference
3-y
between
pLDLT
pDDLT
(adjusted
hazard
ratio
[HR]
0.72;
P
=
0.550)
as-treated
(HR
1.22;
0.741).
No
delisted
group,
whereas
86
(42%)
group;
primarily
because
death
(46
[50%])
medical
improvement
(24
[28%]).
Alcohol
use
since
time
documented
29
(13%)
patients;
immortal
bias
found
HR
1.07;
0.900)
2.95;
0.130).
Conclusions.
Patients
benefit
intention
lower
rates
waitlist
dropout
delisting,
attributable
mortality
or
deterioration,
should
be
encouraged
pursue
this
option.
Zeitschrift für Gastroenterologie,
Journal Year:
2025,
Volume and Issue:
63(02), P. 133 - 138
Published: Feb. 1, 2025
Abstract
Globally,
many
liver
transplantation
programs
require
adherence
to
a
6-month
abstinence
period
in
cases
of
alcohol-associated
disease.
Especially
decompensation,
such
as
acute-on-chronic
failure
(ACLF),
the
severity
disease
often
makes
it
impossible
reach
this
interval,
leading
increasing
critical
scrutiny
fixed
period.
The
prognostic
relevance
is
also
not
firmly
established.
In
present
study,
we
analyze
all
patients
who
were
presented
for
at
German
center
due
caused
by
Retrospective
analyses
with
did
complete
Out
83
initially
considered,
78
included
final
analysis.
underwent
(n=16)
had
significantly
better
5-year
survival
rate
(81.3%
vs.
24.2%;
p
<
0.001).
ACLF
and
multiple
organ
dysfunctions
(ACLF
Grade
3),
resulted
improved
rate.
Patients
an
3
transplanted
died
within
first
six
months
after
decompensation
(92.5%
mortality).
All
surviving
transplant
recipients
continued
abstaining
from
alcohol
until
most
recent
evaluation
point
(average
follow-up
time
963
days).
experiencing
alcohol-related
clearly
benefit
transplantation,
irrespective
whether
they
meet
criterion.
This
stipulated
waiting
increasingly
debated
current
discussions.
Our
findings
emphasize
that
ACLF,
when
transplanted,
face
significant
mortality
risks.
Such
insights
should
be
factored
into
tailored
treatment
decisions.
Liver Transplantation,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 29, 2024
Hazardous
alcohol
consumption
is
the
leading
cause
of
liver
disease
worldwide.
Alcohol-associated
hepatitis
(AH)
an
acute
and
serious
presentation
alcohol-associated
that
associated
with
high
short-term
mortality.
Medical
management
remains
limited
to
corticosteroid
therapy
intensive
nutrition
but
improves
survival
in
<50%
individuals.
Liver
transplantation
(LT)
increasingly
recognized
as
a
treatment
option
for
many
patients
AH
may
lead
greater
benefits
than
medical
alone.
The
rate
waitlistings
LTs
has
doubled
recent
years,
especially
United
States.
Several
studies
from
West
have
reported
early
LT
be
successful,
where
deceased
donor
norm.
challenges
living
centers,
particularly
those
AH,
are
unique
previously
not
been
discussed
depth.
In
this
review,
we
aim
discuss
LDLT
respect
candidate
selection,
ethical
considerations,
disparities
LDLT,
post-LT
relapse,
measures
prevent
them
while
also
addressing
definitions
outcomes
early-living
AH.
Alimentary Pharmacology & Therapeutics,
Journal Year:
2024,
Volume and Issue:
59(9), P. 1049 - 1061
Published: March 12, 2024
Summary
Background
Alcohol‐associated
hepatitis
(AH)
is
a
severe
inflammatory
form
of
alcohol‐associated
liver
disease
(ALD)
that
carries
high
mortality
rate.
Early
transplantation
for
AH
increasingly
available.
However,
specific
criteria
referral
and
selection
remain
subject
debate.
Aims
To
provide
narrative
review
the
natural
history,
diagnostic
indications
early
AH.
Methods
We
searched
PubMed
articles
published
through
August
2023.
Key
search
terms
were
‘alcoholic
hepatitis,’
‘alcohol‐associated
‘abstinence,’
‘alcohol
relapse,’
‘liver
transplantation.’
Results
Previously,
six‐month
period
alcohol
abstinence
was
required
before
patients
with
ALD
considered
transplantation.
studies
in
recent
years
have
demonstrated
that,
among
carefully
selected
patients,
who
received
transplants
much
higher
survival
rates
than
similarly
did
not
undergo
(77%
vs.
23%).
Despite
these
successes,
remains
controversial,
as
typically
undergone
treatment
use
disorder,
ensuing
risk
returning
to
use.
Conclusions
While
has
benefits,
many
would
disorder.
An
integrated
approach
evaluating
candidacy
needed.